Home NEWS AND MEDIA

NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA

19 Dec 2023

Related news

05 / Dec 2025

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma
Learn more
11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more
03 / Jun 2025

NeuExcell Therapeutics' NXL-004 Gene Therapy Shows Positive Early Results in Treating Recurrent Malignant Glioblastoma
Learn more